Stockscreener 앱 받기
0.7534
5.36%
-0.0427
Psyence Biomedical Ltd 주식(PBM)의 최신 뉴스
Gainers Report: Why Psyence Biomedical Ltd stock could benefit from AI revolutionSell Signal & Real-Time Chart Pattern Alerts - moha.gov.vn
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TMX Newsfile
Psyence Biomedical (NASDAQ:PBM) Trading Down 6.1% – Here’s Why - Defense World
How Psyence Biomedical Ltd. stock performs in weak economyJuly 2025 Price Swings & Weekly Chart Analysis and Trade Guides - Улправда
Published on: 2025-12-20 18:04:24 - Улправда
Will Psyence Biomedical Ltd. stock benefit from upcoming earnings reportsJuly 2025 Decliners & Technical Buy Zone Confirmations - Улправда
Investment Review: Is Psyence Biomedical Ltd. stock attractive for hedge fundsDay Trade & Safe Capital Growth Plans - moha.gov.vn
Psyence Biomedical’s psilocybin approved for Phase IIb trial use By Investing.com - Investing.com Nigeria
{Company Name} Stock Soars on Exciting Developments - StocksToTrade
Psyence Biomedical stock rises after ethics approval for psilocybin trial By Investing.com - Investing.com South Africa
Psyence Biomedical stock rises after ethics approval for psilocybin trial - Investing.com India
Psyence Biomedical Ltd. Announces Approval for Use of Psylabs' Psilocybin Product in Phase IIb Clinical Trial - marketscreener.com
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial - The Manila Times
Psyence BioMed announces approval for use of Psylabs' psilocybin product in phase IIb clinical trial - marketscreener.com
Psyence Biomedical’s psilocybin approved for Phase IIb trial use - Investing.com
Psyence BioMed Announces Approval For Use Of Psylabs’ Psilocybin Product In Phase IIb Clinical Trial - TradingView — Track All Markets
Psychedelic therapy trial for patients with cancer moves forward in Australia - Stock Titan
Will Psyence Biomedical Ltd. Equity Warrant stock gain from government policies2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Can Psyence Biomedical Ltd. stock rebound after recent weakness2025 Risk Factors & Weekly Top Performers Watchlists - DonanımHaber
New Highs: Will Psyence Biomedical Ltd. stock benefit from upcoming earnings reportsForecast Cut & Real-Time Sentiment Analysis - Улправда
Will Psyence Biomedical Ltd. stock beat EPS estimatesPortfolio Performance Report & Low Risk Entry Point Tips - ulpravda.ru
Why Psyence Biomedical Ltd. Equity Warrant stock is popular among millennialsWeekly Gains Report & Fast Gaining Stock Strategy Reports - Улправда
Is Psyence Biomedical Ltd. Equity Warrant stock dividend yield sustainableJuly 2025 Selloffs & Weekly Consistent Profit Watchlists - Улправда
Why Psyence Biomedical Ltd. Equity Warrant stock remains a top recommendation2025 Bull vs Bear & Low Risk High Reward Trade Ideas - Улправда
How geopolitical tensions affect Psyence Biomedical Ltd. stock2025 Trading Recap & AI Powered Trade Plan Recommendations - Улправда
Psyence Biomedical Ltd. (PBM) -5.7% in After-hours: Despite No Clear Catalyst - Stocks Telegraph
Psyence BioMed Advances Phase IIb Clinical Trial and Expands Board - MSN
Check out these key findings about Psyence Biomedical Ltd (PBM) - setenews.com
Rapid Surge: Psyence Biomedical’s Unexpected Stock Movement - StocksToTrade
Psyence BioMed (PBM) Stock: Drives Forward with Phase IIb Trial and Unique Longevity Science Position - parameter.io
Psyence Biomedical Ltd. (PBM) Stock: Drops, But Company Pushes Forward with Groundbreaking Psychedelic Therapies - parameter.io
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science - Asianet Newsable
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science - The Manila Times
Bull Run: Why Psyence Biomedical Ltd stock appeals to dividend seekersTrade Performance Summary & Long-Term Growth Portfolio Plans - moha.gov.vn
How Psyence Biomedical Ltd. Equity Warrant stock benefits from global expansionJuly 2025 Market Mood & Reliable Entry Point Alerts - Newser
Will Psyence Biomedical Ltd. Equity Warrant stock remain a Wall Street favoriteWeekly Gains Report & Reliable Volume Spike Trade Alerts - Newser
Will Psyence Biomedical Ltd. Equity Warrant stock sustain high P E ratiosAnalyst Downgrade & Safe Entry Trade Signal Reports - Newser
Is Psyence Biomedical Ltd. stock attractive for growth ETFsPortfolio Risk Report & Reliable Entry Point Trade Alerts - Newser
Price to earnings ratio of Psyence Biomedical Ltd. Warrant 20242028 on Psyence Biomedical – NASDAQ:PBMWW - TradingView
Psyence Biomedical (PBM) Stock Analysis Report | Financials & Insights - Benzinga
Psyence Biomedical (NASDAQ:PBM) Trading Down 2.5% – Should You Sell? - Defense World
Psyence Biomedical Ltd. (PBM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Psyence Biomedical : The Future of Human Longevity Will Be Transformational – And Nature May Hold the Key - marketscreener.com
Psyence BioMed leads longevity research on psilocybin - Longevity.Technology
Its Stock Has Paid Off Big Time For Psyence Biomedical Ltd - Setenews
Breakout Move: Why Psyence Biomedical Ltd. Equity Warrant stock is popular among millennialsEntry Point & Safe Capital Growth Stock Tips - moha.gov.vn
Psyence Biomedical launches psilocybin longevity research program By Investing.com - Investing.com Nigeria
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program - Asianet Newsable
Psyence Biomedical launches psilocybin longevity research program - Investing.com
0.90%
자본화:
|
볼륨(24시간):